Evidence map›Paper›PMID 34349842›Full record

ArticleTherapeutic advances in medical oncology2021

FOLFIRINOX relative dose intensity and disease control in advanced pancreatic adenocarcinoma.

Antonin Vary, Loïc Lebellec, Frédéric Di Fiore, Nicolas Penel, Claire Cheymol, Emilia Rad, Farid El Hajbi, Astrid Lièvre, Julien Edeline, André Michel Bimbai and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in medical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 1 country.

Antonin VaryLille University, Lille, France.
Loïc LebellecLille University, Lille, France Medical Oncology.
Frédéric Di FioreMedical Oncology Department, Henri Becquerel Center, Rouen, France.
Nicolas PenelLille University, Lille, France.
Claire CheymolOnco-Hematology Department, Saint Vincent de Paul Hospital, Lille, France.
Emilia RadMedical Oncology Department, Victor Provo Hospital, Roubaix, France.
Farid El HajbiMedical Oncology Department, Oscar Lambret Center, Lille, France.
Astrid LièvreDepartment of Gastroenterology, CHU Pontchaillou, Rennes, France.
Julien EdelineMedical Oncology Department, Eugène Marquis Center, Rennes, France.ORCID https://orcid.org/0000-0002-8289-7741
André Michel BimbaiBiostatistics and Methodology Unit, Oscar Lambret Center, Lille, France.
Marie-Cécile Le DeleyBiostatistics and Methodology Unit, Oscar Lambret Center, Lille, France.
Anthony TurpinUniversity of Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020 - UMR-S 1277 - Canther-Cancer Heterogeneity, Plasticity and Resistance to Therapies, Lille, France.ORCID https://orcid.org/0000-0002-2282-0101
Centre Oscar Lambret · FRUniversité de Lille · FRCentre Eugène Marquis · FRCentre Hospitalier de Roubaix · FRCentre National de la Recherche Scientifique · FRHôpital Saint-Vincent-de-Paul · FRInserm · FRUniversité de Rouen Normandie · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMost patients with advanced pancreatic adenocarcinoma (PA) treated with FOLFIRINOX experience adverse events requiring dose reduction. We aimed to assess the association between relative dose intensity (RDI) and disease control in a European setting.

methodsWe retrospectively included patients with advanced PA treated with three or more cycles of FOLFIRINOX between 2011 and 2018 in six French centers. We computed the cumulative single-agent RDI (csRDI) before the first reassessment for each FOLFIRINOX agent (oxaliplatin, irinotecan, 5FU bolus, and 5FU intravenous infusion) and the cumulative multi-drug RDI (cmRDI) of their combination. The association between RDI and disease control or objective response at first reassessment was evaluated using multivariable logistic regression models controlling for performance status, liver metastases, and center.

resultsWe included 243 patients. Median csRDIs were 81%, 79%, 75%, and 85% for oxaliplatin, irinotecan, 5FU bolus, and 5FU intravenous infusion, respectively. Median cmRDI was 80%. None of the RDIs was significantly associated with disease control or objective response. Including RDI in a clinical model did not improve its ability to predict disease control; the area under the curve was 0.79 (95% CI: 0.73-0.85) with RDI

conclusionPragmatic dose adjustments of FOLFIRINOX should be made by oncologists without considering a loss of effect.

Indexed as

advanced pancreatic cancerdisease control rateFOLFIRINOXrelative dose intensityresponse rate

Identifiers

PMID34349842
PMCPMC8287268
OpenAlexW3186595270

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.